MEDIA

In November 2024, AMS BioteQ made its debut at one of the world’s largest medical exhibitions, MEDICA 2024 in Düsseldorf, Germany, while also laying the groundwork for its upcoming participation in Arab Health 2025 in Dubai, UAE.

AMS BioteQ, founded by Dr. George Tsai in 2018, focuses on drug development and innovative medical materials research. The company leverages Taiwan’s unique natural resources and has successfully expanded into the global anti-infection market.

AMS BioteQ (stock code: 6864) is making waves in Japan with its innovative technologies and flexible production capabilities.

Medical Japan 2024 Tokyo, a premier healthcare exhibition encompassing medical care, elderly care, diagnostics, and drug development, is set to commence on Oct. 9th at Makuhari Messe, Chiba. AMS BioteQ, a Taiwanese biotech startup, will make its return appearance, showcasing groundbreaking medical innovations that have already garnered significant attention prior to the exhibition.

AMS BioteQ , stock code: (6864-TW)) announced on August 30 that it has signed a distribution contract for its innovative medical material 'SIPSIP Foam Wound Dressing' with a group of medical institutions in Japan, securing its first overseas order.

AMS BioteQ (Stock Code: 6864), a biotech company, announced on July 11 that its innovative medical device "SIPSIP Foam Wound Dressing" has successfully obtained the first-class medical device sales permit from Japan's Pharmaceuticals and Medical Devices Agency (PMDA), officially entering the Japanese market.

The National Pharmaceutical Trade Fair (PHARMCHINA) was grandly held in Shanghai, China, from May 15 to 17, 2024. It is a large-scale professional exhibition for health nutrition and wellness products in China.

CPHI Japan was held grandly from April 17 to 19 this year (2024).

In pursuit of academic exchange, fostering industry-academia collaboration, and talent cultivation, the School of Pharmacy at Kaohsiung Medical University and AMS BioteQ recently signed a memorandum of understanding (MOU) to enhance industry-academia exchange, promote the development of the domestic biopharmaceutical industry, and lay the foundation for pharmaceutical research talent cultivation.

The "Connecting with Ukraine" economic revitalization event, orchestrated by the Japan International Cooperation Agency (JICA), convened from February 15th to 17th, 2024. This gathering served as a platform uniting businesses, manufacturers, and research institutions from Japan and Ukraine, pooling their resources to aid in the post-war reconstruction endeavors of Ukraine.

On January 18th, AMS BioteQ (TPE: 6864) announced the successful approval of its application for a novel invention patent in Taiwan titled “ARTIFICIAL DRESSING AND USE OF ARTIFICIAL DRESSING FOR PROMOTING WOUND” by the Intellectual Property Office of the Ministry of Economic Affairs, R.O.C.

AMS BioteQ (TPE: 6864) announced on 11th Dec. last year that its innovative medical care product, "SIPSIP Foam," the wound dressing made of its patented bioengineering technology ExtrO, has successfully obtained the registration number issued by the U.S. FDA.